TGF-beta RI

TGF-beta RI Molekülinformation

Englischer Name	Transforming growth factor beta receptor 1	Anzahl der inverkehr gebrachten Arzneimittel	0
Anzahl der klinischen Arzneimittel	7	Target-Alias	EC 2.7.11，TGF-beta type I receptor，Serine/threonine-protein kinase receptor R4，TGFBR1，Activin A receptor type II-like protein kinase of 53kD，Transforming Growth Factor Beta Receptor 1，Transforming Growth Factor-Beta Receptor Type I，Activin A Receptor Type II-Like Kinase， 53kDa，Activin Receptor-Like Kinase 5，TGFR-1，ALK-5，ALK5，SKR4，Mutant Transforming Growth Factor Beta Receptor I，TGF-Beta Receptor Type-1，TGF-Beta Receptor Type I，EC 2.7.11.30，ACVRLK4，LDS1A，LDS2A，AAT5，LDS1，TBRI，ESS1，MSSE，TbetaR-I，Transforming Growth Factor Beta Receptor I，Multiple Self-Healing Squamous Epithelioma，TBR-I，Receptor， Transforming Growth Factor-beta Type I，EC:2.7.11.30
Höchste Forschungs- und Entwicklungsphase	Phase 3 Clinical

Englischer Name	Transforming growth factor beta receptor 1
Target-Alias	EC 2.7.11，TGF-beta type I receptor，Serine/threonine-protein kinase receptor R4，TGFBR1，Activin A receptor type II-like protein kinase of 53kD，Transforming Growth Factor Beta Receptor 1，Transforming Growth Factor-Beta Receptor Type I，Activin A Receptor Type II-Like Kinase， 53kDa，Activin Receptor-Like Kinase 5，TGFR-1，ALK-5，ALK5，SKR4，Mutant Transforming Growth Factor Beta Receptor I，TGF-Beta Receptor Type-1，TGF-Beta Receptor Type I，EC 2.7.11.30，ACVRLK4，LDS1A，LDS2A，AAT5，LDS1，TBRI，ESS1，MSSE，TbetaR-I，Transforming Growth Factor Beta Receptor I，Multiple Self-Healing Squamous Epithelioma，TBR-I，Receptor， Transforming Growth Factor-beta Type I，EC:2.7.11.30
Anzahl der inverkehr gebrachten Arzneimittel	0
Anzahl der klinischen Arzneimittel	7
Höchste Forschungs- und Entwicklungsphase	Phase 3 Clinical

TGF-beta RI Produktliste

Attribut
Protein (2)
Produktbibliothek
Online (2)
Spezies
Human (2)
Etikett
Llama IgG Fc Tag (1)Fc Tag (1)
Marker
Unconjugated (2)

Produktnummer	Spezies	Expressionssystem	Produktbeschreibung	Proteinstruktur	Reinheit	Eigenschaften	Vorbestellen/Bestellen
TG1-H5254	Human	HEK293	Human TGF-beta RI Protein, Fc Tag, low endotoxin (MALS verified)				In den Warenkorb legen
TG1-H5259	Human	HEK293	Human TGFR-1 / ALK-5 / TGF-beta receptor type-1 Protein, Llama IgG2b Fc Tag (SPR verified)				In den Warenkorb legen

Gesamtmenge2

TGF-beta RI Molekülhintergrund

TGF type I receptor also called the activin receptor-like kinase 5 (ALK5) and involved in TGF signaling. TGFβ signaling is mediated by the interaction of TGFβ ligands (TGFβ 1, 2 or 3) with cell surface receptors, the TGF type I, type II and type III receptors. Signaling is initiated by binding of TGF to the TGF type II receptor forming a ligand-receptor complex which interacts with the TGF type I receptor.

TGF-beta RI Molekülalias

TGFR-1, ALK-5, TGF-beta receptor type-1, Activin receptor-like kinase 5

Klinische Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Indikationen	Klinische Studie
Galunisertib	LY-2157299	Phase 3 Clinical	Eli Lilly And Company	Amyotrophic Lateral Sclerosis; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Glioblastoma; Glioma; Liver Neoplasms; Metastatic breast cancer; Myelodysplastic Syndromes; Nasopharyngeal Carcinoma; Neoplasm Metastasis; Neoplasms; Pancreatic Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Rectal Neoplasms; Solid tumours; Triple Negative Breast Neoplasms	Details
GF-101	GFH-018; GF-101; GFH018	Phase 2 Clinical	Genfleet Therapeutics (Shanghai) Co Ltd	Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Liver Neoplasms; Pancreatic Neoplasms; Solid tumours	Details
Tosposertib phosphate	TU-2218; NCE401; NCE-401	Phase 2 Clinical	TiumBio Co Ltd	Idiopathic Pulmonary Fibrosis; Solid tumours	Details
Ontunisertib	ORG-129; AGMB-129	Phase 2 Clinical	Origo Biopharma Sociedad Litmitada	Crohn Disease	Details
TRK-250	TRK-250; BNC-1021	Phase 1 Clinical	Bonac Corp	Idiopathic Pulmonary Fibrosis	Details
Oxinseti	SH-3051	Phase 1 Clinical	Nanjing Sanhome Pharmaceutical Co Ltd	Liver Neoplasms; Solid tumours	Details
AGMB-447	AGMB-447; ORG-447	Phase 1 Clinical	AgomAb Therapeutics NV	Idiopathic Pulmonary Fibrosis	Details